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Low hemoglobin oxygen saturation (SpO
2
) is common in Sickle Cell Anemia (SCA) and associated with complications including
stroke, although determinants remain unknown. We investigated potential hematological, genetic, and nutritional predictors of
daytime SpO
2
in Tanzanian children with SCA and compared them with non-SCA controls. Steady-state resting pulse oximetry,
full blood count, transferrin saturation, and clinical chemistryweremeasured.Median daytime SpO
2
was 97% (IQ range 94–99%) in
SCA (N = 458), lower (𝑃 < 0.0001) than non-SCA (median 99%, IQ range 98–100%;N = 394).Within SCA, associations with SpO
2
were observed for hematological variables, transferrin saturation, body-mass-index z-score, hemoglobin F (HbF%), genotypes, and
hemolytic markers; mean cell hemoglobin (MCH) explained most variability (𝑃 < 0.001, Adj 𝑟2 = 0.09). In non-SCA only age
correlated with SpO
2
. 𝛼-thalassemia 3.7 deletion highly correlated with decreased MCH (Pearson correlation coefficient −0.60,
𝑃 < 0.0001). In multivariable models, lower SpO
2
correlated with higher MCH (𝛽-coefficient −0.32, 𝑃 < 0.001) or with decreased
copies of𝛼-thalassemia 3.7 deletion (𝛽-coefficient 1.1,𝑃 < 0.001), and independently in bothmodelswith lowerHbF% (𝛽-coefficient
0.15, 𝑃 < 0.001) and Glucose-6-Phosphate Dehydrogenase genotype (𝛽-coefficient −1.12, 𝑃 = 0.012). This study provides evidence
to support the hypothesis that effects on red cell rheology are important in determining SpO
2
in children with SCA. Potential
mechanisms and implications are discussed.
1. Introduction
Hemoglobin oxygen desaturation in the absence of acute
illness is common in children with Sickle Cell Anemia
(SCA), and is associated with higher cerebral blood flow
velocities [1, 2], and with risk of complications including
stroke [3]. The underlying mechanisms of hemoglobin oxy-
gen desaturation in SCA are poorly understood but may
involve the severity of anemia [4] as well as differences
in hemoglobin oxygen affinity compared to hemoglobin A
(HbA), with increased expression of 2.3 DPG in hemoglobin
S (HbS) resulting in a right-shifted hemoglobin oxygen
affinity curve and other differences in red cell physiol-
ogy [5]. Other potential causes include a history of acute
chest syndrome and reduced pulmonary [6] and cardiac
function [7]. Coinheritance of alpha-thalassemia deletions
and glucose-6-phosphate deficiency (G6PD) may affect the
degree of anemia [8, 9] whilst alpha-thalassemia status
modifies red cell indices [10–12] and rheology [13], as
can iron status [14]. We therefore investigated potential
hematological, genetic, and nutritional predictors of day-
time hemoglobin oxygen saturation in Tanzanian pediatric
patients homozygous for HbS (SCA) and in non-SCA local
controls.
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2. Patients and Methods
Ethical permission was granted by the Muhimbili Uni-
versity of Health and Allied Sciences Ethics Committee
(MU/RP/AECNoI.XII/77). Written informed consent was
obtained from parents or guardians in their own language.
2.1. Patients and Clinical Procedures. Children (less than 17
years) with SCA (HbSS genotype) were enrolled in the SCD
cohort study at Muhimbili National Hospital, Dar-es-Salaam
[15]. Resting pulse oximetry data (Masimo Radical, Masimo
Corporation, USA) and blood samples were collected at
routine outpatient clinic visits between November 2007
and December 2008. Analysis was limited to data collected
at a single steady-state time point. A strict definition of
steady state was employed (temperature <37.5∘C, no malaria
parasitaemia, no reported pain, no blood transfusion within
90 days or hospital admission within 30 days on either side
of the selected time point) and determined to be clinically
well by the attending doctor. All cohort children are routinely
prescribed folate supplementation (5mg/day).
Non-SCA children were those who presented for sickle
testing between October 2004 and December 2008 but who
had HbAA or HbAS by hemoglobin electrophoresis. None of
the children had malaria parasitaemia or fever (temperature
>37.4∘C) and all were clinically well.
2.2. Laboratory Procedures. Blood samples were collected
between 8 and 10 am. Full blood counts were performed
using an automated cell counter (Pentra 60, Horiba ABX,
Kyoto, Japan). Serum iron and total iron binding capacity
were measured in serum samples stored at −80∘C (Architect
C8000, Abbott, New York, USA). Transferrin saturation was
calculated from serum iron and total iron binding capacity.
Lactate dehydrogenase (LDH) and bilirubin (total and con-
jugated) were measured in fresh serum samples (Architect
C8000, Abbott, New York) by Muhimbili Central Pathology
Laboratory.
Children attending screening for sickle status were typed
for HbS by alkaline Hb electrophoresis (Helena, Sunderland,
Tyne and Wear, UK). Children enrolled in the Muhim-
bili Sickle cohort also had hemoglobin fractions, including
HbF, quantified by HPLC using the 𝛽-thalassemia Short
Programme on the Variant analyzer (BioRad, Hercules,
CA, USA). In addition, children enrolled in the Muhim-
bili Sickle Cohort had HbSS status confirmed by genotype
and were genotyped for the 3.7 alpha-thalassemia deletion
using a PCR-based method and agarose gel visualization
as per published methods [16] and the 202- and 376-single
nucleotide polymorphisms (SNPs) for glucose 6-phosphate
dehydrogenase deficiency (G6PD) and HbS using multiplex
Sequenom [17].
2.3. Data Analysis. Data were analyzed using STATA 11-
IC (StataCorp, College Station, TX, USA). Daytime SpO
2
is not normally distributed due to an excess of observa-
tions having the maximum possible value of 100% and
a skewed distribution towards the lower values. The data
are not normalized by the usual log transformations. Thus
we investigated the use of negative binomial regression of
count data using a new variable of SpO
2
-100 compared to
zero-inflated negative binomial regression. Vuong tests [18]
indicated no strong consistent preference for either models
across the explanatory variables tested. As we had no prior
hypotheses that mechanisms to predict 100% versus <100%
SpO
2
may differ from mechanisms underlying the degree of
desaturation, we selected the negative binomial regression
model.We next compared the results of thesemodels to those
from simple linear regression of the nontransformed data and
observed no major differences in the results. Whilst analysis
of the residuals from the linear regression models indicated
some skew, this was not judged to be sufficient to render
the results invalid, which were in agreement with those from
the better fitting negative binomial regression models. Thus
for ease of presentation and interpretation the results of the
linear regression models are presented. 𝑃 values <0.05 were
considered significant.
3. Results
Complete hematological, genetic, and iron status (transferrin
saturation) data were available for 458 SCA children. None
of the children were receiving hydroxyurea or routine blood
transfusions. None of the children had received more than
4 blood transfusions in their lifetime. In addition, complete
hematological and pulse oximetry data were available for 394
non-SCA children, although transferrin saturation data were
only available in a small subset of 62 children and genotyping
was not conducted in these controls. Pulse oximetry, hema-
tological and iron status data for the two groups of children
are summarized in Table 1. Of the 458 SCA children, 239
were boys (52%) with amean age of 9.7 y (SD 4.3 y) compared
to 212 boys (54%) in the 394 non-SCA children with a mean
age 7.0 y (SD 4.7 y). In the SCA children median daytime
SpO
2
was 97% (IQ range 94–99%) (Table 1), significantly
lower (Wilcoxon rank sum test; 𝑃 < 0.0001) than in the
non-SCA children (median 99%; IQ range 98–100%) (Table 1
and Figure 1). Hemoglobin concentration, red cell indices
(red blood cell count (RBC), mean cell hemoglobin (MCH),
and mean cell hemoglobin concentration (MCHC), mean
cell volume (MCV)), and markers of hemolysis (LDH and
unconjugated bilirubin) were significantly different between
the SCA and non-SCA groups (Table 1). The proportion
of SCA children with low transferrin saturation (<16%)
indicating probable iron deficiency, was 28% (126/458) but
was lower than that in non-SCA Tanzanian control children
(32/62, 52%) (Table 1). Only 9 (2%) of the SCA and none of
the non-SCA patients had high transferrin saturation (>55%)
which might indicate iron over-load. Forty-one percent
of the SCA children (192/458) were heterozygous for the
3.7 alpha-thalassemia deletion and 17% were homozygous
(78/458). Eleven percent of SCA children were heterozygous
females for both the −202 and −376 G6PD single nucleotide
polymorphisms (SNPs) which results in a moderate
phenotype [19], whilst a further 12% (54/458) of SCA children
were affected homozygous females or affected males.
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Table 1: Daytime pulse oximetry data, haematological and haemolytic indices and iron status in Tanzanian SCA and non-SCA children.
Variable SCA children with daytime
oximetry (𝑁 = 458)
Non-SCA children with daytime
oximetry (𝑁 = 394)
Pulse oximetry
Median daytime SpO2 (%) 97 (IQ range 94–99) 99 (IQ range 98–100)∗∗∗
Haematology
Mean hemoglobin∗ (g/dL) 7.4 (SD 1.17) 10.9 (SD 2.2)∗∗∗
Mean red cell count × 10−9 2.89 (SD 0.66) 4.71 (SD 0.86)∗∗∗
Mean cell hemoglobin concentration (g/dL) 31.9 (SD 1.52) 32.3 (SD 1.60)∗∗
Mean cell hemoglobin (pg/cell) 26.1 (SD 3.31) 23.6 (SD 3.86)∗∗∗
Mean cell volume∗ (fL) 79.5 (SD 15.28) 73.1 (SD 9.21)∗∗∗
Median reticulocyte % (𝑁 = 440/335) 12.8 (IQ range 9.1–16.4) 2.4 (IQ range 0.8–6.7)∗∗∗
Median hemoglobin F (Hb%) (𝑁 = 316/60)† 4.7 (IQ range 2.8–7.9) 0.6 (IQ range 0.2–1.0)∗∗∗
Haemolytic markers
Median lactate dehydrogenase (IU) (𝑁 = 427/340) 762 (533–1121) 498 (367–671)∗∗∗
Median unconjugated bilirubin (𝜇mol/L) (𝑁 = 417/181) 33.3 (IQ range 18.2–61.1) 7.2 (IQ range 3.5–12.5)∗∗∗
Iron status
Median transferrin saturation (%) (𝑁 = 458/62) 20.9 (IQ range 15.4–27.7) 14.9 (IQ range 9.1–25.3)∗∗
Median serum iron (𝜇mol/L) (𝑁 = 458/62) 11.5 (SD 5.7) (range 8.6–14.9) 10.0 (SD 8.5) (range 5.8–17.2)
Mean serum TIBC (𝜇mol/L) (𝑁 = 458/62) 55.3 (SD 10.9) (range 47.7–62.75) 70.5 (SD 22.3) (range 50.4–84.3)∗∗∗
Iron deficiency transferrin saturation < 16% 126/458 (27.5%) 32/62 (51.6%)∗∗∗
†Within the SCA children, HbF% was not assessed at the same time point as the hematology and SpO2 data and was limited to children older than 5 years at
the time of measurement of HbF% & SpO2. HbF% was available for some non-SCA children and was measured at the same time point as the SpO2.
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001.
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Figure 1: Distribution of daytime hemoglobin oxygen saturation in children with SCA compared to non-SCA.
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Table 2: Predictors of daytime SpO2 in SCA.
Explanatory variable 𝛽-coefficient 𝑃 value Adj 𝑟2
Hematological indices
Hemoglobin (g/dL) 0.35 0.007 0.014
RBC × 10−9 1.10 <0.001 0.050
MCHC (g/dL) −0.57 <0.001 0.073
MCH −0.29 <0.001 0.090
MCV (fl) −0.02 0.041 0.007
HbF% (𝑁 = 315)† 0.12 <0.001 0.026
Iron status and nutritional status
Transferrin saturation % −0.03 0.03 0.008
BMI Z-score (𝑁 = 451) 0.18 0.049 0.006
Hemolytic markers
Lactate dehydrogenase (IU) {natural log} (𝑁 = 427) −0.72 0.011 0.013
Unconjugated bilirubin (𝜇mol/L) {natural log} (𝑁 = 415) −0.34 0.029 0.009
𝛼-thalassemia genotype
3.7 heterozygote versus Wild Type 1.29 <0.001
3.7 homozygote versus Wild Type 2.04 <0.001 0.056∗
G6PD genotype
Heterozygote females versus Wild Type −0.52 0.276
Homozygote females and affected males versus Wild Type −1.30 0.005 0.014∗
𝑁 = 458 unless otherwise stated. ∗Adj 𝑟2 for whole model. †Analysis of SpO2 limited to those with HbF and SpO2 measured when patients were 5 years or
older.
Predictors of SpO
2
in SCA are shown in Table 2. Within
the SCA population all of the hematological variables were
significantly associated with SpO
2
. Higher hemoglobin, RBC,
and HbF% were associated with greater SpO
2
, whilst higher
MCH, MCHC, and MCV were associated with lower SpO
2
.
MCH was the single biggest contributor to the variation
in SpO
2
as indicated by the still modest adjusted 𝑟2 value
of 0.09. There was weak evidence of a negative association
between transferrin saturation and SpO
2
. In the non-SCA
population the same hematological variables were tested for
associations with SpO
2
, as well as Hb phenotype, AS versus
AA. However, the only predictor of SpO
2
in this group was a
positive association for age (beta coefficient 0.05, 𝑃 = 0.024)
with no evidence to suggest even weak effects of any of the
hematological indices.
In the SCA population for whom genotypes were avail-
able, coinheritance of the alpha-thalassemia 3.7 genotype
was associated with increased SpO
2
, whilst co-inheritance of
G6PD deficiency was associated with decreased SpO
2
.
Pair-wise associations between the different explanatory
variables for daytime SpO
2
within the SCA group were
investigated and are presented in full in Supplementary Table
1 available online at http://dx.doi.org/10.1155/2013/472909.
Alpha-thalassemia genotype was highly associated with all
of the hematological variables, with the number of 3.7
deletions being associated with higher hemoglobin (Pear-
son correlation coefficient 0.23); RBC count (0.55); lower
MCV (−0.24), MCHC (−0.32), and MCH (−0.60); and also
lower hemolyticmarkers, particularly unconjugated bilirubin
(−0.26), all with 𝑃 values <0.0001. Interestingly, presence of
the 3.7 alpha-thalassemia deletion was also associated with
improved nutritional status as determined by body-mass-
index 𝑧-score. Higher MCH and MCV were associated with
lower hemoglobin in the SCA population whilst HbF% was
associated with higher hemoglobin. Transferrin saturation
was positively associated with hemoglobin (0.17) and also
higher MCH (0.33), both 𝑃 values <0.0005, but was not
associated with MCV. Interestingly, G6PD genotype was not
significantly associated with any of the other variables.
Correlations between the hematological variables were
similar in the non-SCA population compared to SCA (data
not shown) except that higher MCV was correlated with
higher hemoglobin (0.64, 𝑃 < 0.001) but was not associated
with RBC count and no association was apparent between
hemoglobin and MCHC.
In multivariable models predicting SpO
2
, the inclu-
sion of MCH with alpha-thalassemia genotype resulted
in a diminished and nonsignificant association for alpha-
thalassemia. However, in models including either MCH or
alpha-thalassemia there were an independent effect of HbF%
and weak evidence of an independent effect of G6PD limited
to affected males and homozygote females (Supplementary
Table 2), but with the greatest variation explained by a model
including MCH and HbF% (adjusted 𝑟2 = 0.15, 𝑃 < 0.001,
𝑁 = 315).
4. Discussion
Few studies have attempted to determine the hematological
or genetic correlates of daytime SpO
2
. In this study we report
that higher daytime SpO
2
in children with SCA is associated
with higher red cell count and hemoglobin, but with lower
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MCH or MCHC. Coinheritance of the alpha-thalassemia 3.7
deletion in our SCA population is strongly associated with
increased hemoglobin, red cell count and decreased MCH
and MCHC and also with increased SpO
2
, but not inde-
pendently of these factors. Thus the basis of the association
between alpha-thalassemia genotype and SpO
2
would appear
to be via its effects on red cell indices. In Kenyan nonsickle
populations, alpha-thalassemia 3.7 deletion copy number is
also associated with slightly increased hemoglobin levels and
increased red cell counts, but effects on anaemia appear to be
modulated by sickle trait status [20]. This suggests that the
decreased anemia and increased red cells observed in SCA
plus alpha-thalassemia results from decreased rate of red cell
destruction, proposed to be due to lower HbS concentration
in red cells, and thus reduced HbS polymerization which
is concentration dependent as well as being increased by
desaturation [11]. This is supported by the observation that
alpha thalassemia was associated with lower levels of LDH
and unconjugated bilirubin as markers of hemolysis. Red cell
count and hemoglobin were not associated with SpO
2
when
adjusting for MCH and thus anemia does not appear to be a
direct cause of low SpO
2
in our population. A beneficial effect
of alpha thalassemia on daytime SpO
2
has also been observed
in Jamaican children with SCA, [21] but in contrast to our
study, there were also independent effects of hemoglobin,
whilst neither MCH, or MCHC was associated with SpO
2
[21].
It is interesting to note that within the non-SCA popula-
tion none of the tested variables were associated with SpO
2
.
This may have been the result of the reduced variability in
SpO
2
in the non-SCA population, or reflect sickle-specific
effects of red cell indices on SpO
2
. Again, this contrasts with
observations in older Jamaican childrenwhowereHbAA (15–
18 years) in whom hemoglobin and MCV (but not MCH or
MCHC) were associated with SpO
2
.
Our observation of a beneficial effect of co-inheritance
of alpha-thalassemia on daytime SpO
2
in children with SCA
appears to be in direct contrast to our previous observation
of a negative effect on mean overnight SpO
2
, measured in a
small group (𝑁 = 30) of similar aged Tanzanian children
with SCA [22]. However, this effect of alpha-thalassemia
appeared to be confounded by the strong negative association
between transferrin saturation and mean overnight SpO
2
.
We concluded that this association was most likely the result
of reverse causality from nocturnal chronic and intermittent
hemoglobin desaturation causing increased transferrin satu-
ration due to upregulation of hypoxia-inducible factor, which
has downstream effects of increasing iron absorption, which
may also be increased by alpha-thalassemia [20]. Thus we
suggest that in a larger dataset, alpha-thalassemia may also
have a beneficial effect on mean overnight SpO
2
.
Similar to Jamaican [21] and American SCA children
[6], HbF% was positively and independently associated with
SpO
2
. It is not possible in the current study to determine if an
effect of HbF% is via direct effects on increased hemoglobin
oxygen affinity or through indirect effects on rates of sick-
ling or red cell rheology. Interestingly alpha-thalassemia
was also associated with increased HbF%, perhaps through
increased rate of release of immature red cells from ineffective
erythropoiesis. The co-inheritance of G6PD deficiency was
negatively associated with SpO
2
. As there was no evidence
of an association between G6PD and levels of hemolytic
markers, as has been observed previously in SCA [9], the
effect on SpO
2
is likely through another mechanism.
Lower daytime and nocturnal SpO
2
in SCA are associated
with poor clinical outcomes. This includes elevated cerebral
blood flow velocities [1, 2] and an increased risk of stroke [3,
23]. Co-inheritance of alpha-thalassemia is protective against
elevated cerebral blood flow velocities in children with SCA
[24, 25] and is associated with reduced stroke risk [26], whilst
G6PD increases the risk [24]. Thus the mechanisms behind
these associations may, at least in part, be through effects on
hemoglobin oxygen saturation and subsequent endothelial
dysfunction [27, 28] as well as other potential effects of red
cell deformability and endothelial adhesion [24].
In conclusion, in our population of Tanzanian children
with SCA, the strongest predictor of lower SpO
2
is increased
mean cell hemoglobin, which is strongly correlated with a
decreased copy number of the 3.7 alpha-thalassemia deletion.
The degree of anemia, red cell count, and hemolytic markers
do not independently correlate with SpO
2
, thus suggest-
ing that effects of mean cell hemoglobin and the alpha-
thalassemia genotype on SpO
2
are mediated through effects
on red cell rheology.
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